Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378119 | 0.90 | ERBB2 (0.77) | ERBB2EGFR | |
| SCHEMBL4076780 | 0.86 | ERBB2 (0.73) | ERBB2EGFR | |
| SCHEMBL4072543 | 0.85 | ERBB2 (0.71) | ERBB2EGFR | |
| SCHEMBL3377629 | 0.85 | ERBB2 (0.71) | ERBB2EGFR | |
| SCHEMBL3376628 | 0.85 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL3376338 | 0.85 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL4073165 | 0.85 | ERBB2 (0.72) | ERBB2EGFR | |
| SCHEMBL3375094 | 0.84 | ERBB2 (0.89) | ERBB2EGFR | |
| SCHEMBL3380349 | 0.84 | ERBB2 (0.89) | ERBB2EGFR | |
| SCHEMBL5062788 | 0.84 | ERBB2 (0.89) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221616-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1877398-B1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| EP-1877398-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117523-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221616-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.